Overview

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Status:
Withdrawn

Trial end date:
2015-11-01

Target enrollment:

Participant gender:

Summary

This is a Multicenter, Open-label, Phase 1b Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Phase:

Phase 1

Details

Lead Sponsor:

Millennium Pharmaceuticals, Inc.